» Articles » PMID: 31749652

Cognition and Addiction


Overview
Specialty Neurology
Date 2019 Nov 22
PMID 31749652
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

In this targeted review, we summarize current knowledge on substance-use disorder (SUD)-related cognitive deficits, the link between these deficits and clinical outcomes, and the cognitive training, remediation, and pharmacological approaches that have the potential to rescue cognition. We conclude that: (i) people with SUDs have moderate deficits in memory, attention, executive functions, and decision-making (including reward expectancy, valuation, and learning); (ii) deficits in higher-order executive functions and decision-making are significant predictors of relapse; (iii) cognitive training programs targeting reward-related appetitive biases, cognitive remediation strategies targeting goal-based decision-making, and pharmacotherapies targeting memory, attention, and impulsivity have potential to rescue SUD-related cognitive deficits. We suggest avenues for future research, including developing brief, clinically oriented harmonized cognitive testing suites to improve individualized prediction of treatment outcomes; computational modeling that can achieve deep phenotyping of cognitive subtypes likely to respond to different interventions; and phenotype-targeted cognitive, pharmacological, and combined interventions. We conclude with a tentative model of neuroscience-informed precision medicine.
.

Citing Articles

The repeatable battery for the assessment of neuropsychological status (RBANS) and substance use disorders: a systematic review.

Hoiland K, Raudeberg R, Egeland J Subst Abuse Treat Prev Policy. 2025; 20(1):12.

PMID: 40065390 PMC: 11895193. DOI: 10.1186/s13011-025-00640-2.


Impaired arbitration between reward-related decision-making strategies in Alcohol Users compared to Alcohol Non-Users: a computational modeling study.

Ramakrishnan S, Shaik R, Kanagamani T, Neppala G, Chen J, Fiore V NPP Digit Psychiatry Neurosci. 2025; 3(1):1.

PMID: 39759090 PMC: 11698690. DOI: 10.1038/s44277-024-00023-8.


The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.

Pulido-Saavedra A, Borelli A, Kitaneh R, Alrafayia M, Jalilian-Khave L, Funaro M Expert Opin Pharmacother. 2024; 26(2):133-146.

PMID: 39708346 PMC: 11786980. DOI: 10.1080/14656566.2024.2446623.


The associations among type D personality and nomophobia, metacognitions about smartphone use, smartphone addiction in Chinese university freshmen: a two-wave study.

Xie Y, Luo S BMC Psychiatry. 2024; 24(1):620.

PMID: 39289640 PMC: 11409663. DOI: 10.1186/s12888-024-06073-8.


Cognitive Dysfunction in the Addictions (CDiA): A Neuron to Neighbourhood Collaborative Research Program on Executive Dysfunction and Functional Outcomes in Outpatients Seeking Treatment for Addiction.

Nikolova Y, Ruocco A, Felsky D, Lange S, Prevot T, Vieira E medRxiv. 2024; .

PMID: 39252904 PMC: 11383479. DOI: 10.1101/2024.08.30.24312806.


References
1.
Robertson C, Ishibashi K, Chudzynski J, Mooney L, Rawson R, Dolezal B . Effect of Exercise Training on Striatal Dopamine D2/D3 Receptors in Methamphetamine Users during Behavioral Treatment. Neuropsychopharmacology. 2015; 41(6):1629-36. PMC: 4832026. DOI: 10.1038/npp.2015.331. View

2.
Gladwin T, Wiers C, Wiers R . Cognitive neuroscience of cognitive retraining for addiction medicine: From mediating mechanisms to questions of efficacy. Prog Brain Res. 2016; 224:323-44. DOI: 10.1016/bs.pbr.2015.07.021. View

3.
Verdejo-Garcia A, Chong T, Stout J, Yucel M, London E . Stages of dysfunctional decision-making in addiction. Pharmacol Biochem Behav. 2017; 164:99-105. DOI: 10.1016/j.pbb.2017.02.003. View

4.
Dominguez-Salas S, Diaz-Batanero C, Lozano-Rojas O, Verdejo-Garcia A . Impact of general cognition and executive function deficits on addiction treatment outcomes: Systematic review and discussion of neurocognitive pathways. Neurosci Biobehav Rev. 2016; 71:772-801. DOI: 10.1016/j.neubiorev.2016.09.030. View

5.
Kampman K, Lynch K, Pettinati H, Spratt K, Wierzbicki M, Dackis C . A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend. 2015; 155:105-10. PMC: 4582003. DOI: 10.1016/j.drugalcdep.2015.08.005. View